Patents Examined by Niloofar Rahmani
  • Patent number: 12291539
    Abstract: The present disclosure provides compounds and methods useful in the treatment and suppression of cancer, for example, useful for treating or suppressing cancers characterized by KRAS G12C. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Grant
    Filed: July 24, 2024
    Date of Patent: May 6, 2025
    Assignee: Frontier Medicines Corporation
    Inventors: Snahel Patel, Philip A. Gerken, Monika Jane Williams
  • Patent number: 12290511
    Abstract: The present invention aims to find a pharmaceutical preparation which treats or prevents glaucoma or ocular hypertension and is effective for patients with inadequate efficacies of glaucoma or ocular hypertension therapeutic agents. It has been found that omidenepag, an ester thereof, or a salt thereof has an excellent intraocular pressure lowering efficacy on patients with inadequate efficacies of other glaucoma or ocular hypertension therapeutic agents. Therefore, the omidenepag, the ester thereof, or the salt thereof of the present invention is useful as a pharmaceutical preparation which can treat or prevent glaucoma or ocular hypertension even in patients with inadequate efficacies of other glaucoma or ocular hypertension therapeutic agents.
    Type: Grant
    Filed: May 10, 2023
    Date of Patent: May 6, 2025
    Assignee: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Hisashi Kawata, Noriko Kawabata, Naveed Shams
  • Patent number: 12286430
    Abstract: Disclosed herein is a compound of Formula (I) for inhibiting both Bcl-2 wild type and mutated Bcl-2, in particular, Bcl-2 G101V and D103Y, and a method of using the compound disclosed herein for treating dysregulated apoptotic diseases.
    Type: Grant
    Filed: April 14, 2021
    Date of Patent: April 29, 2025
    Assignee: BeiGene, Ltd.
    Inventors: Hai Xue, Yunhang Guo, Zhiwei Wang
  • Patent number: 12281112
    Abstract: The present disclosure relates to inhibitors of NLRP3 useful in the treatment of diseases and disorders inhibited by said protein and having the Formula (I):
    Type: Grant
    Filed: July 3, 2024
    Date of Patent: April 22, 2025
    Assignee: Ventus Therapeutics U.S., Inc.
    Inventor: Stéphane Dorich
  • Patent number: 12281115
    Abstract: This invention provides rho-associated protein kinase (ROCK) inhibiting compounds for therapeutic applications as described further herein.
    Type: Grant
    Filed: October 14, 2024
    Date of Patent: April 22, 2025
    Assignee: Avicenna Biosciences, Inc.
    Inventor: Thomas Maxwell Kaiser
  • Patent number: 12275705
    Abstract: A compound represented by a formula (I) or a formula (II): (in the formulas (I) and (II), A represents an oxygen atom or a sulfur atom, X1 represents a halogeno group or the like, m represents the number of X1 groups and is any integer of 0 to 5, Z represents a group represented by a formula (Z-1) or a formula (Z-2), a bond marked with a symbol * means a bond with a carbonyl group or a thiocarbonyl group in a pyridinium salt, Y represents a substituted or unsubstituted C2-6 alkenylene group, Q represents a naphthalene ring or a 6- to 10-membered heteroaryl ring, X2 represents a substituted or unsubstituted C1-6 alkyl group or the like, X3 represents a halogeno group or the like, n represents the number of X3 groups and is any integer of 0 to 4, Zq? represents a counter ion, and q represents a valence of the counter ion and is 1 or 2.
    Type: Grant
    Filed: May 26, 2020
    Date of Patent: April 15, 2025
    Assignee: NIPPON SODA CO., LTD.
    Inventors: Riho Taguchi, Hiroto Suzuki, Kotaro Shibayama, Takao Iwasa, Kento Iwata
  • Patent number: 12269802
    Abstract: Disclosed herein are methods and processes of preparing vadadustat and pharmaceutically acceptable salts thereof, and intermediates of formula (I) and their salts useful for the synthesis of vadadustat.
    Type: Grant
    Filed: June 13, 2023
    Date of Patent: April 8, 2025
    Assignee: Akebia Therapeutics, Inc.
    Inventors: Boris I. Gorin, Christopher M. Lanthier, Anne Buu Chau Luong, James Densmore Copp, Javier Gonzalez, Sascha Jautze, Erich Kraus, Alan O'Connor
  • Patent number: 12269821
    Abstract: The present invention relates to novel antitumor agents and pharmaceutically acceptable salts thereof, processes and intermediates for the manufacture of these novel constrained cyclic frameworks of general formula I and II, and medicaments containing such compounds.
    Type: Grant
    Filed: July 25, 2019
    Date of Patent: April 8, 2025
    Assignee: UNIVERISTY OF SHARJAH
    Inventors: Taleb H. Altel, Vunnam Srinivasulu, Saleh Ibrahim, Paul Schilf
  • Patent number: 12252489
    Abstract: The present disclosure provides compounds of Formula (I), useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 (“TREM2”). This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula (1).
    Type: Grant
    Filed: May 4, 2021
    Date of Patent: March 18, 2025
    Assignees: AMGEN Inc., Vigil Neuroscience, Inc.
    Inventors: Lara C. Czabaniuk, Timothy Hopper, Jonathan B. Houze, Gwenaella Rescourio, Vincent Santora, Haoxuan Wang, Ryan D. White, Alice R. Wong, Yongwei Wu
  • Patent number: 12247036
    Abstract: The present invention relates to compounds of formula (Ib), wherein R1 to R3, M and L are as described herein, and their pharmaceutically acceptable salt, enantiomers and diastereomers thereof, and compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: August 22, 2024
    Date of Patent: March 11, 2025
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Jianguo Chen, Lei Guo, Haixia Liu, Hong Shen, Junwei Xi, Weixing Zhang, Dan Zhao, Wei Zhu
  • Patent number: 12240846
    Abstract: The present disclosure relates to compounds and compositions for inhibition of Bcr-Abl tyrosine kinases, methods of preparing said compounds and compositions, and their use in the treatment of various cancers, such as chronic myeloid leukemia (CML).
    Type: Grant
    Filed: August 11, 2023
    Date of Patent: March 4, 2025
    Assignee: Enliven Inc.
    Inventors: Joseph P. Lyssikatos, Samuel Kintz, Li Ren
  • Patent number: 12234217
    Abstract: A method is disclosed for preparing compounds of Formula 1 by combining compounds of Formulae 2 and 3 and a sulfonyl chloride in a continuous process.
    Type: Grant
    Filed: November 22, 2019
    Date of Patent: February 25, 2025
    Assignees: FMC CORPORATION, FMC AGRO SINGAPORE PTE. LTD.
    Inventor: Steven T. Booth
  • Patent number: 12234236
    Abstract: The present disclosure describes GLP-1R modulating compounds that are useful for treating GLP-1R-mediated diseases or conditions,
    Type: Grant
    Filed: September 13, 2024
    Date of Patent: February 25, 2025
    Assignee: Ascletis Pharma (China) Co., Limited
    Inventors: Bin Liang, Jinzi Jason Wu, Bailing Yang
  • Patent number: 12221442
    Abstract: This disclosure relates to GLP-1 agonists of Formula (I), including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.
    Type: Grant
    Filed: January 26, 2024
    Date of Patent: February 11, 2025
    Assignee: Gasherbrum Bio, Inc.
    Inventors: Qinghua Meng, Weiqiang Xing, Haizhen Zhang, Xichen Lin, Hui Lei, Andrew Jennings
  • Patent number: 12213969
    Abstract: The present invention is directed to inhibitors of histone deacetylases (HDACs) such as HDAC6, and their use in the treatment of diseases such as cell proliferative diseases (e.g., cancer), neurological (e.g., neurodegenerative disease or neurodevelopmental disease), inflammatory or autoimmune disease, infection, metabolic disease, hematologic disease, or cardiovascular disease.
    Type: Grant
    Filed: June 29, 2023
    Date of Patent: February 4, 2025
    Assignee: VALO HEALTH, INC.
    Inventors: Xiaozhang Zheng, Pui Yee Ng, Mary-Margaret Zablocki
  • Patent number: 12215087
    Abstract: The present disclosure relates to compounds that act as inhibitors of NLRP3 inflammasomes; pharmaceutical compositions comprising the compounds; and methods of treating disorders associated with inflammation and inflammaging, including hearing loss and other diseases associated with aging.
    Type: Grant
    Filed: July 17, 2023
    Date of Patent: February 4, 2025
    Assignee: BioAge Labs, Inc.
    Inventors: George Hartman, Paul Humphries, Kevin Edward Leif Wilhelmsen
  • Patent number: 12209086
    Abstract: The present invention provides compounds of the formula: for use in the treatment of systemic sclerosis, fibrosis (e.g. pulmonary fibrosis), achondroplasia, thanatophoric dysplasia (e.g. type I), severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN), muenke syndrome or cancer.
    Type: Grant
    Filed: December 13, 2023
    Date of Patent: January 28, 2025
    Assignee: ELI LILLY AND COMPANY
    Inventors: Adedoyin David Abraham, Desta Doro Bume, Kevin Ronald Condroski, Robert Alan Hazlitt, Timothy Scott Kercher, Andrew Terrance Metcalf, Kaveri Balan Urkalan, Shane Michael Walls, Andrew Karl Dilger
  • Patent number: 12208141
    Abstract: The disclosure relates to anti-cancer compounds derived from nuclear steroid receptor binders, to products containing the same, as well as to methods of their use and preparation.
    Type: Grant
    Filed: September 22, 2023
    Date of Patent: January 28, 2025
    Assignee: NUVATION BIO INC.
    Inventors: David Hung, Son Minh Pham, Sarvajit Chakravarty, Jiyun Chen, Jayakanth Kankanala, Jeremy D. Pettigrew, Anup Barde, Anjan Kumar Nayak
  • Patent number: 12195479
    Abstract: A five-membered-fused six-membered compound, and a preparation method therefor and a pharmaceutical composition and the use thereof. The five- and six-membered compound is a compound as shown in formula I, II or III. The compound has an inhibitory effect on FLT3 and/or IRAK4.
    Type: Grant
    Filed: December 19, 2023
    Date of Patent: January 14, 2025
    Assignee: HANGZHOU POLYMED BIOPHARMACEUTICALS, INC.
    Inventors: Jason Shaoyun Xiang, Lei Wu, Rui Xu, Qiang Zhang, Gang Yang, Michael Xiang, Mixue Tong, Camille Xiang, Yuxin Liu, Suyue Wang, Rui Yang
  • Patent number: 12195460
    Abstract: The present disclosure relates to inhibitors of NLRP3 useful in the treatment of diseases and disorders inhibited by said protein.
    Type: Grant
    Filed: July 3, 2024
    Date of Patent: January 14, 2025
    Assignee: Ventus Therapeutics U.S., Inc.
    Inventor: Stéphane Dorich